Jay Venkatesan, Angion CEO
June 30, 2022 07:11 AM EDT
R&D

An­gion, still reel­ing from past de­feats, scraps a PhII kid­ney dis­ease study af­ter 'un­ex­pect­ed' safe­ty event

Max Gelman

Senior Editor

Faced with a litany of set­backs over its lead pro­gram last year, An­gion Bio­med­ica is now re­port­ing a new ob­sta­cle in a fol­low-up can­di­date. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times